Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process ...

One-year data suggest allogeneic stem cell-derived islet-cell therapy could become a future option for those with type 1 ...

"While most organs are thought to be shaped by static, brick-like cells, our study highlights the powerful role of dynamic, migrating cells—and how they work together to sculpt living tissue ...

In prostate and breast cancer cells, removing CD36 blocked the cancer-fighting power of these drugs. This wasn’t just true for PROTACs but for other large drugs too, like doxorubicin and navitoclax.

Abnormal amino acid metabolism supports cancer cell proliferation, invasion, and immune evasion in hepatocellular carcinoma (HCC). Previous research exploring amino acid metabolism in HCC has ...

Extensive-stage small-cell lung cancer (ES-SCLC), which accounts for approximately 15% of lung cancers, is an aggressive and highly lethal disease. The current standard of care is induction therapy ...

Heart muscle cells do something similar, issuing electrical “heave-ho” signals that make the organ beat. Skin and other epithelial cells, however, were thought to be silent; they form barrier ...

Leaders from the world of cell and gene therapy, including molecular geneticists, immunotherapists, physicians, nonprofit directors, and patient advocates, shared their personal stories and policy ...

The loss of the Y chromosome in tumour cells is linked to poor outcomes for people with cancer 1, but this genetic alteration might also compromise immune cells that would otherwise fight the ...